Last updated: June 25, 2026

Desloratadine and Pseudoephedrine Sulfate 24 Hour market dynamics and financial trajectory: pricing, demand drivers, exclusivity, and generic risk

Desloratadine and pseudoephedrine sulfate 24 hour is a combination allergy product (second-generation antihistamine plus oral decongestant) whose market trajectory is shaped by (1) limited durability of branded share in the face of multi-competitor generics, (2) state and federal restrictions that periodically tighten access to oral decongestants, (3) payer and formulary channeling into lower-cost alternatives, and (4) the strength and age of the Orange Book patent estate tied to specific branded dosage forms and release designs. For commercial planning, the key financial question is not long-term “blockbuster” growth but whether the product can hold share and pricing against generic penetration in the 24-hour category and whether any remaining formulation or method-of-use IP meaningfully delays low-cost equivalents.

What is the branded and generic competitive landscape for desloratadine and pseudoephedrine sulfate 24 hour?

Featured snippet answer: The market is structurally exposed to generic entry because the active ingredients (desloratadine and pseudoephedrine sulfate) are established and widely manufactured. Competitive intensity depends on the specific branded product’s dosage form (24-hour extended-release), strength, and FDA approval history, with pricing pressure typically driven by multi-source generics and pharmacy channel mix.

Key competitive buckets

Branded 24-hour combination
Typically sold in a fixed-dose ratio under brand trade names tied to a specific extended-release formulation.
Generic extended-release combinations
Lower-cost alternatives with the same labeled indication set and dosing scheme, competing at retail and through PBM formularies.
Therapeutic substitutes outside the combination
- Desloratadine alone (antihistamine monotherapy)
- Pseudoephedrine sulfate products (decongestant monotherapy, subject to OTC and behind-the-counter controls depending on jurisdiction)
- Other second-generation antihistamine plus decongestant combinations (market-share substitutes, not IP-linked)

Where share typically concentrates

Retail pharmacy: highest sensitivity to PBM preferred status and patient cost sharing.
Mail order: benefits from formulary positioning and channel contracting.
Hospital/clinic: typically minor for OTC-like allergy products unless administered in specific workflows or dispensed under plan protocols.

How do formulation, dosing, and release profile affect demand for 24-hour desloratadine plus pseudoephedrine?

Featured snippet answer: 24-hour extended release matters because it reduces dosing frequency versus immediate-release decongestant schedules, improving adherence and physician and patient acceptance, which in turn can raise initial uptake and sustain share longer than immediate-release equivalents.

What “24 hour” changes commercially

Adherence economics: fewer daily doses can reduce missed dosing for symptomatic seasonal allergic rhinitis (SAR) and chronic rhinitis populations.
Patient preference: a once-daily decongestant schedule can be a differentiator when payers require prior authorization only for higher-cost options.
Dispensing behavior: pharmacy staff and consumers often treat extended-release combinations as “preferred convenience,” which affects conversion in the early commercialization window and during seasonal peaks.

Common formulation drivers that affect pricing power

Bioavailability and performance: if generics demonstrate equivalent performance at lower prices, the brand loses its convenience premium.
Manufacturing complexity: extended-release matrix or coated-tablet processes can create slower early generic adoption, but this advantage usually decays with established ANDA supply chains.

What are the demand drivers for the desloratadine and pseudoephedrine sulfate 24-hour category?

Featured snippet answer: Seasonal allergic rhinitis volume and the decongestant demand cycle drive the category, with pricing influenced by PBM coverage decisions and regulatory friction around oral pseudoephedrine access.

Primary demand contributors

Seasonality (SAR and viral URIs)
- Allergy seasons expand prescription and OTC-like dispensing for antihistamines.
- Respiratory congestion episodes expand pseudoephedrine combination usage.
Access friction
- Periodic tightening of pseudoephedrine purchase controls can shift demand toward alternative decongestant strategies or prescriber choice patterns.
Payer channeling
- Formulary tier placement drives utilization and net price.
- Plans often steer toward generics with rebates and contracting.

Secondary demand contributors

Product switching from monotherapy
- Patients using an antihistamine alone who later add decongestants are a source pool for combination growth.
Age and comorbidity
- Older populations may face higher sensitivity to decongestant side effects, which can reduce category elasticity even when congestion is present.
Competing allergy platforms
- Intranasal steroids, intranasal antihistamines, leukotriene receptor antagonists, and combination nasal therapies can displace oral regimens on both efficacy and tolerability grounds.

How does pseudoephedrine regulation influence sales and long-term market stability?

Featured snippet answer: Oral pseudoephedrine access constraints tend to increase volatility at retail and can shift demand to alternative therapies, while the prescription channel is generally more resilient than OTC access.

What changes in the market

OTC pressure shifts to controlled access
- If retail purchase restrictions tighten, consumers may substitute to:
  - prescription-only decongestant strategies, or
  - alternative agents without pseudoephedrine.
Procurement and distribution friction
- Compliance burdens for retailers can reduce shelf stock and dampen OTC conversion rates.
Net effect on extended-release combination
- When pseudoephedrine restrictions reduce OTC decongestant availability, combination uptake through prescription plans can become comparatively more attractive, but only if payers keep the combination in covered tiers.

When does desloratadine and pseudoephedrine sulfate 24 hour lose exclusivity, and what does that mean for revenue?

Featured snippet answer: Revenue erosion typically follows the expiration of formulation and combination-specific IP and the launch of lower-cost ANDA equivalents. In an established fixed-dose combination category, net revenue decline is usually stepwise: brand share falls at first generic entry, then collapses toward generic class pricing after multiple competitors enter.

Commercial implications of exclusivity expiry

Pricing: branded net price drops sharply after first generic launches as PBMs rebid and pharmacies rationalize inventory.
Volume: branded unit volume falls as prescribers and pharmacists switch to class alternatives.
Mix: any remaining differentiated subpopulation (tolerability or patient preference) migrates to equivalents over time.

What is the Orange Book status of desloratadine and pseudoephedrine sulfate 24 hour?

Featured snippet answer: The Orange Book typically lists patents tied to the brand’s NDA and to any associated exclusivities for the specific dosage form and strength. In mature products combining established actives, the most economically relevant listings are usually expiring or already expired patents on formulation, composition, and method-of-use.

How to interpret the Orange Book for commercial planning

Patent types with greatest practical impact
- Drug substance patents for old actives often have long expired.
- Formulation/composition-of-matter and specific extended-release delivery patents often control the timeline for generic substitutions.
Expiration vs. market entry
- A patent expiration date is not the same as first generic shipment.
- Generic manufacturers may launch at risk depending on litigation and Paragraph IV outcomes.

No Orange Book listing or expiration timeline is included here because the provided input does not contain the NDA label name, NDA number, or the specific branded product identifier for “desloratadine and pseudoephedrine sulfate 24 hour.”

Which patent estate risks drive generic entry for this combination?

Featured snippet answer: Generic entry risk is usually driven by whether the branded extended-release tablet is protected by enforceable formulation patents and whether ANDA challengers file Paragraph IV certifications against those patents.

Patent categories that commonly matter in fixed-dose extended-release combinations

Composition-of-matter for the extended-release mechanism
Method-of-use patents for specific indications or dosing regimens
Manufacturing/process patents
Combination claims that define the fixed-dose ratio and release profile

How these translate to market timing

Strong formulation IP delays ANDA approval or blocks at-risk launches.
If formulation IP is weak, expired, or not asserted successfully, generic entrants converge quickly and net prices compress.

No patent numbers, asserted patents, or Paragraph IV history are included because specific Orange Book, NDA, and litigation docket identifiers were not provided.

What patent litigation or settlement dynamics typically affect this class?

Featured snippet answer: In mature combination allergy products, litigation most often determines whether at-risk launches are blocked temporarily and whether settlement triggers “skinny” entry dates, launch design workarounds, or shared market territories.

Common settlement patterns to model

No-entry settlements (brand pays to delay generic launch)
Authorized-entry settlements (brand agrees to allow generic entry at a specified time with non-infringing formulations)
“Design-around” manufacturing changes (generics modify release systems to avoid asserted patents)

No litigation timeline is included because the exact product’s NDA and brand are not specified.

How does FDA regulatory status influence market access for generics and substitutes?

Featured snippet answer: Generic competition depends on the FDA approval pathway (ANDA vs. 505(b)(2)) and whether generic drug products have granted bioequivalence and quality approvals for the same dosage form and release characteristics.

What to model in commercial forecasts

ANDA review timelines
- Approval timing can shift generic availability by quarters.
Labeling equivalence
- If generics differ in labeling details (pediatric age limits, contraindications, dosing instructions), prescriber adoption can be slower.
Manufacturing continuity
- Supply disruptions affect competitive share even when approvals are granted.

No FDA approval milestones are included because the NDA/applicant IDs for the specific “24 hour” combination were not provided.

How does this combination compare with competing allergy regimens on commercial performance?

Featured snippet answer: Oral antihistamine plus decongestant combinations tend to face substitution pressure from intranasal steroid and intranasal antihistamine therapies, and from antihistamine monotherapy when patients tolerate congestion less or when payers prefer non-decongestant regimens.

Substitution map

Against desloratadine monotherapy
- Combination wins when congestion control is a patient priority.
Against intranasal corticosteroids
- Intranasals often win on guideline adherence for persistent SAR, reducing oral combination demand.
Against alternative oral decongestant combinations
- Generic availability and PBM preferred status determine the winner more than drug-specific pharmacology.

What revenue trajectory should investors or planners expect for desloratadine and pseudoephedrine sulfate 24 hour after generic entry?

Featured snippet answer: After generic entry, branded revenue typically declines rapidly in the first 6 to 18 months, then stabilizes at a much smaller base if brand manufacturers retain any residual differentiation (channel relationships, rebates, or patient preference). In multi-source environments, class pricing compresses and margins trend toward generic-like levels.

Revenue drivers to quantify in a forecast

Net price per unit (post-generic step-down)
Market share by channel (retail vs mail order vs institutional)
Seasonal elasticity
PBM formulary changes (tier placement, prior auth triggers)
Supply competition (number of approved generic SKUs and manufacturing reliability)

No numeric revenue or market size figures are included because the prompt does not provide the specific NDA name/strength and does not include a source dataset for historical sales (e.g., IQVIA, Symphony, company filings, or FDA/IMS estimates).

Which commercialization risks most likely reduce growth for the category?

Featured snippet answer: The most material risks are generic price compression, payer formulary exclusion, regulatory or retailer friction related to pseudoephedrine, and clinical substitution toward intranasal therapies.

Specific risk list

Formulary displacement
- Plans prefer lower-cost generics and often exclude branded decongestant combinations.
Patient tolerability and contraindication constraints
- Decongestant side effect profiles can reduce adherence and limit eligible patient populations.
Therapy switching
- Patients and clinicians shift toward nasal steroid regimens for persistent symptoms.

How many competitors are likely in the 24-hour fixed-dose combination market, and what does that mean for pricing?

Featured snippet answer: The combination category typically reaches multi-source competition once formulation-specific IP expires and ANDA approvals consolidate. More approved SKUs increase downward pressure on net price and reduce brand share.

Pricing behavior to expect

Initial generic entry
- First generic sets the “floor,” but brand may temporarily retain higher price through rebates.
Second and third entrants
- Consolidate the bottom of the price range and can force PBM re-contracting.
Multi-source parity
- Retail shelf and mail order availability normalize, leaving brand differentiation as largely rebate- and contract-driven.

Key Takeaways

Desloratadine plus pseudoephedrine sulfate 24 hour is an allergy combination whose market depends on seasonal demand plus oral decongestant access conditions.
Commercial upside is limited by rapid competitive erosion after generic entry and by payer-driven channeling into lower-cost options.
The major determinants of revenue trajectory are (1) extended-release formulation-specific IP and (2) how quickly multiple ANDA equivalents reach stable supply.
Pseudoephedrine regulation can add volatility, shifting demand between OTC access and prescription coverage.
For financial modeling, forecast net price step-down, channel mix changes, and seasonal volume elasticity around generic launch timing.

FAQs

Do desloratadine plus pseudoephedrine 24-hour generics get substituted automatically at pharmacies?
How do PBM prior authorization rules for decongestant-antihistamine combinations typically impact utilization?
Does extended-release dosing reduce adverse events enough to improve persistence versus immediate-release decongestant combinations?
What label or strength differences can slow generic uptake in the desloratadine-pseudoephedrine class?
How does intranasal therapy displacement change the long-term demand curve for oral antihistamine-decongestant combinations?

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). ANDA pathway information. https://www.fda.gov/

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	1
Patent Applications:	16
DailyMed Link:	DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Ltd	DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	078366-001	Apr 26, 2011		RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

Recent Clinical Trials for DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR